The construction of the new 72,000 ft² facility is slated to finish in 2014. It will allow Boehringer to handle production of active pharmaceutical ingredients used in early development activities.
If approved, the products will move on to the company’s full-scale R&D facilities in Ohio and Virginia, as well as Germany and Italy.
In August, Boehringer broke ground on a $42.5m safety assessment building for non-clinical safety studies. The building is scheduled to be completed in 2013.
Boehringer Ingelheim US Operations Development senior vice president Jim Baxter said the pharmaceutical giant chose to keep the new facility in Connecticut because it is vital to the rest of the research that is done in Ridgefield.
Both the projects, which represent an investment of more than $100m in Connecticut, are part of more than $350m in capital investments in the US in 2011, reported courant.com.